Single-Domain Antibodies As Therapeutics against Human Viral Diseases
In full-size formats, monoclonal antibodies have been highly successful as therapeutics against cancer and immune diseases. However, their large size leads to inaccessibility of some epitopes and relatively high production costs. As an alternative, single-domain antibodies (sdAbs) offer special adva...
Main Authors: | Yanling Wu, Shibo Jiang, Tianlei Ying |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-12-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2017.01802/full |
Similar Items
-
Camelid‐derived single‐chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications
by: Ivan Peyron, et al.
Published: (2020-10-01) -
Camelid Single-Domain Antibodies: Historical Perspective and Future Outlook
by: Mehdi Arbabi-Ghahroudi, et al.
Published: (2017-11-01) -
Construction of Novel Bispecific Single-Domain Antibodies (BiSdAbs) with Potent Antiangiogenic Activities
by: Xianglei Liu, et al.
Published: (2020-03-01) -
Broad Reactivity Single Domain Antibodies against Influenza Virus and Their Applications to Vaccine Potency Testing and Immunotherapy
by: Andrew Tung Yep, et al.
Published: (2021-03-01) -
Single-Domain Antibodies and Their Formatting to Combat Viral Infections
by: Dorien De Vlieger, et al.
Published: (2018-12-01)